Equillium (EQ) Capital Expenditures (2018 - 2026)
Equillium (EQ) posted quarterly Capital Expenditures of $3000.0 for Q1 2026, down 25.0% year-over-year from $4000.0 in Q1 2025, and down 93.18% quarter-over-quarter from $44000.0 in Q4 2025.
Equillium (EQ) Capital Expenditures (2018 - 2026) Analysis & Trends
Equillium (EQ) has reported Capital Expenditures for 9 consecutive years, with $3000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Capital Expenditures fell 25.0% year-over-year to $3000.0; the TTM figure through Mar 2026 stood at $47000.0 (down 32.86% YoY), while the FY2025 annual figure was $48000.0, down 43.53% from the prior year.
- Capital Expenditures eased to $3000.0 in Q1 2026 per EQ's latest filing, from $44000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $276000.0 in Q4 2022 and bottomed at -$274000.0 in Q3 2022.
- Historically, Capital Expenditures has averaged $40909.1 across 5 years, with a median of $35000.0 in 2023.
- Annual changes were most pronounced in 2022 — Capital Expenditures tumbled 956.25% — and 2025, when it soared 1000.0%.
- Equillium's Capital Expenditures stood at $276000.0 in 2022, then sank by 87.32% to $35000.0 in 2023, then plunged by 88.57% to $4000.0 in 2024, then jumped by 1000.0% to $44000.0 in 2025, then sank by 93.18% to $3000.0 in 2026.
- Business Quant data shows EQ's Capital Expenditures at $3000.0 in Q1 2026, $44000.0 in Q4 2025, and $4000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Equillium | 263.86 Mn | 263.86 Mn | - | 3,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,000.00 |
| Jun 30, 2026 | 3,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Mar 31, 2026 | 3,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Dec 31, 2025 | 44,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Mar 31, 2025 | 4,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Dec 31, 2024 | 4,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Jun 30, 2024 | 62,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Mar 31, 2024 | 19,000.00 |
| Dec 31, 2023 | 35,000.00 |
| Dec 31, 2023 | 35,000.00 |
| Dec 31, 2022 | 276,000.00 |
| Dec 31, 2022 | 276,000.00 |
| Sep 30, 2022 | -274,000.00 |
| Sep 30, 2022 | -274,000.00 |